TY - JOUR
T1 - Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors
T2 - a longitudinal analysis and modelling study
AU - Sissoko, Daouda
AU - Duraffour, Sophie
AU - Kerber, Romy
AU - Kolie, Jacques Seraphin
AU - Beavogui, Abdoul Habib
AU - Camara, Alseny Modet
AU - Colin, Géraldine
AU - Rieger, Toni
AU - Oestereich, Lisa
AU - Pályi, Bernadett
AU - Wurr, Stephanie
AU - Guedj, Jeremie
AU - Nguyen, Thi Huyen Tram
AU - Eggo, Rosalind M.
AU - Watson, Conall H.
AU - Edmunds, W. John
AU - Bore, Joseph Akoi
AU - Koundouno, Fara Raymond
AU - Cabeza-Cabrerizo, Mar
AU - Carter, Lisa L.
AU - Kafetzopoulou, Liana Eleni
AU - Kuisma, Eeva
AU - Michel, Janine
AU - Patrono, Livia Victoria
AU - Rickett, Natasha Y.
AU - Singethan, Katrin
AU - Rudolf, Martin
AU - Lander, Angelika
AU - Pallasch, Elisa
AU - Bockholt, Sabrina
AU - Rodríguez, Estefanía
AU - Di Caro, Antonino
AU - Wölfel, Roman
AU - Gabriel, Martin
AU - Gurry, Céline
AU - Formenty, Pierre
AU - Keïta, Sakoba
AU - Malvy, Denis
AU - Carroll, Miles
AU - Anglaret, Xavier
AU - Günther, Stephan
N1 - Publisher Copyright:
© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license
PY - 2017/1/1
Y1 - 2017/1/1
N2 - Background By January, 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been stopped. However, there is concern about persistence of Ebola virus in the reproductive tract of men who have survived EVD. We aimed to use biostatistical modelling to describe the dynamics of Ebola virus RNA load in seminal fluid, including clearance parameters. Methods In this longitudinal study, we recruited men who had been discharged from three Ebola treatment units in Guinea between January and July, 2015. Participants provided samples of seminal fluid at follow-up every 3–6 weeks, which we tested for Ebola virus RNA using quantitative real-time RT-PCR. Representative specimens from eight participants were then inoculated into immunodeficient mice to test for infectivity. We used a linear mixed-effect model to analyse the dynamics of virus persistence in seminal fluid over time. Findings We enrolled 26 participants and tested 130 seminal fluid specimens; median follow up was 197 days (IQR 187–209 days) after enrolment, which corresponded to 255 days (228–287) after disease onset. Ebola virus RNA was detected in 86 semen specimens from 19 (73%) participants. Median duration of Ebola virus RNA detection was 158 days after onset (73–181; maximum 407 days at end of follow-up). Mathematical modelling of the quantitative time-series data showed a mean clearance rate of Ebola virus RNA from seminal fluid of −0·58 log units per month, although the clearance kinetic varied greatly between participants. Using our biostatistical model, we predict that 50% and 90% of male survivors clear Ebola virus RNA from seminal fluid at 115 days (90% prediction interval 72–160) and 294 days (212–399) after disease onset, respectively. We also predicted that the number of men positive for Ebola virus RNA in affected countries would decrease from about 50 in January 2016, to fewer than 1 person by July, 2016. Infectious virus was detected in 15 of 26 (58%) specimens tested in mice. Interpretation Time to clearance of Ebola virus RNA from seminal fluid varies greatly between individuals and could be more than 13 months. Our predictions will assist in decision-making about surveillance and preventive measures in EVD outbreaks. Funding This study was funded by European Union's Horizon 2020 research and innovation programme, Directorate-General for International Cooperation and Development of the European Commission, Institut national de la santé et de la recherche médicale (INSERM), German Research Foundation (DFG), and Innovative Medicines Initiative 2 Joint Undertaking.
AB - Background By January, 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had been stopped. However, there is concern about persistence of Ebola virus in the reproductive tract of men who have survived EVD. We aimed to use biostatistical modelling to describe the dynamics of Ebola virus RNA load in seminal fluid, including clearance parameters. Methods In this longitudinal study, we recruited men who had been discharged from three Ebola treatment units in Guinea between January and July, 2015. Participants provided samples of seminal fluid at follow-up every 3–6 weeks, which we tested for Ebola virus RNA using quantitative real-time RT-PCR. Representative specimens from eight participants were then inoculated into immunodeficient mice to test for infectivity. We used a linear mixed-effect model to analyse the dynamics of virus persistence in seminal fluid over time. Findings We enrolled 26 participants and tested 130 seminal fluid specimens; median follow up was 197 days (IQR 187–209 days) after enrolment, which corresponded to 255 days (228–287) after disease onset. Ebola virus RNA was detected in 86 semen specimens from 19 (73%) participants. Median duration of Ebola virus RNA detection was 158 days after onset (73–181; maximum 407 days at end of follow-up). Mathematical modelling of the quantitative time-series data showed a mean clearance rate of Ebola virus RNA from seminal fluid of −0·58 log units per month, although the clearance kinetic varied greatly between participants. Using our biostatistical model, we predict that 50% and 90% of male survivors clear Ebola virus RNA from seminal fluid at 115 days (90% prediction interval 72–160) and 294 days (212–399) after disease onset, respectively. We also predicted that the number of men positive for Ebola virus RNA in affected countries would decrease from about 50 in January 2016, to fewer than 1 person by July, 2016. Infectious virus was detected in 15 of 26 (58%) specimens tested in mice. Interpretation Time to clearance of Ebola virus RNA from seminal fluid varies greatly between individuals and could be more than 13 months. Our predictions will assist in decision-making about surveillance and preventive measures in EVD outbreaks. Funding This study was funded by European Union's Horizon 2020 research and innovation programme, Directorate-General for International Cooperation and Development of the European Commission, Institut national de la santé et de la recherche médicale (INSERM), German Research Foundation (DFG), and Innovative Medicines Initiative 2 Joint Undertaking.
UR - http://www.scopus.com/inward/record.url?scp=85003441798&partnerID=8YFLogxK
U2 - 10.1016/S2214-109X(16)30243-1
DO - 10.1016/S2214-109X(16)30243-1
M3 - Article
C2 - 27955791
AN - SCOPUS:85003441798
SN - 2572-116X
VL - 5
SP - e80-e88
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 1
ER -